Jiangsu HengRui Medicine Co., Ltd.: Stomach Neoplasms trials

The registry lists 13 Stomach Neoplasms studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 4 are open to participants now and 2 have results posted.

Phase 1 4Phase 2 4Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerRecruitingNCT07110571Phase 2
• Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingNCT07102901Phase 2
• SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenRecruitingNCT06123494Phase 3
• Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCRecruitingNCT04342910Phase 3
• A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerCompletedNCT03472365Phase 2Results posted
• Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerCompletedNCT01512745Phase 3Results posted
• A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing TumorsCompletedNCT04513223Phase 1
• A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic TherapyCompletedNCT03813784Phase 3
• A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer PatientsStatus unknownNCT03026881Phase 1
• Apatinib Dose Titration in Advanced or Metastatic Gastric CancerCompletedNCT02764268Not applicable
• Phase I Study of Pyrotinib in Patients With HER2-positive Solid TumorsStatus unknownNCT02500199Phase 1
• Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerStatus unknownNCT02378389Phase 1
• A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorTerminatedNCT01994213Phase 2